Spotlight on our pipelines: Generation 5
Bpi France featured our innovative project, Liga2Bio
Bpi France featured our innovative project, Liga2Bio
New innovative bioresorbable ligament
The “LIGA2BIO” project benefits from €6.4 million in funding from the French Future Investments Program (PIA), operated by Bpifrance, to develop a new generation artificial ligament that will be bioactive, biointegrable, and biodegradable.
Arc-sur-Tille, May 5, 2017 – Led by Bernard Brulez, CEO of LARS, the “LIGA2BIO” project has been selected under the French Government’s Investments for the Future Program (PIA) in the category “Structuring R&D Projects for Competitiveness” (PSPC). The project aims to develop a bioactive, biointegrable, and biodegradable ligament for the treatment of ligament ruptures. Funded with €6.4 million by Bpifrance in the form of grants and repayable advances, for a total budget of €9 million, the “LIGA2BIO” project represents a true breakthrough therapeutic solution that seeks to revolutionize ligament surgery.
About Movmedix
Driven by our vision to restore infinite mobility to patients suffering from soft tissue injuries, Movmedix continues to evolve toward becoming a global leader in sports medicine. With more than three decades of expertise, we have been at the forefront of the artificial ligament field — pioneering free-fibre technology and designing implants tailored to specific clinical indications.
Building on the strong legacy of our LARS® (Ligament Advanced Reinforcement System) product range, we remain committed to developing innovative and disruptive solutions that address the evolving needs of surgeons and improve patient outcomes worldwide.
